Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
May 03, 2014 12:00 AM

Insurers brace for high-cost Sovaldi

Paul Demko and Virgil Dickson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    A 12-week treatment course for Sovaldi costs $84,000, leading to access fears.

    The new hepatitis C drug Sovaldi has become an $84,000 dilemma for private and public insurers, particularly Medicaid plans.

    UnitedHealth Group, the largest private insurer, estimated its Sovaldi treatment costs at $100 million during the first three months of 2014. Aetna tabulated its first-quarter costs for the drug at $30 million, while Cigna estimated spending $10 million so far this year.

    WellPoint initially projected costs for hepatitis C virus (HCV) treatment would double in 2014. But after racking up $50 million in costs during the first three months of the year, the insurer announced that it was boosting anticipated HCV-related expenses for 2014 by an additional $100 million. About 40% of WellPoint's expenses were from commercial plans, 35% from Medicaid plans and 25% from Medicare Advantage plans.

    “Hep C is the biggest issue right now,” WellPoint CEO Joseph Swedish said on a call with investors last week. “It's the watch item for the industry.”

    Sovaldi has a reported cure rate of higher than 80%. But the $84,000 price of the drug for a full 12-week course of treatment has led to fears that many who could benefit won't be able to get it, and that the costs will prove financially unsustainable for insurers and public-healthcare programs. Treating every one of the estimated 3.2 million Americans with HCV would cost about $270 billion, four times the cost of the entire Medicare Part D prescription drug program in 2013, according to a report from the Kaiser Family Foundation.

    Jeff Myers, president and CEO of the trade group Medicaid Health Plans of America, estimated that Sovaldi could cost state Medicaid programs as much as $1.5 billion a year. If costs for other current and emerging HCV drugs are added, spending on prescriptions for the disease could top $2 billion annually, he said. Johnson & Johnson's HCV drug Olysio costs $66,000 for 12 weeks of treatment, and Solvaldi's maker, Gilead Sciences, is expected to release another offering in October. “We need to look at how to best provide treatment so that we don't destabilize the program,” Myers said.

    Medicare is also at risk. In March, the CMS decided to cover HCV screening for all Medicare beneficiaries born between 1945 and 1965. The agency is expected to release a final rule on covering the screenings by June.

    Still, Medicaid programs and plans have the most pressing concerns because a disproportionate share of those with HCV are low-income individuals. Medicaid Health Plans of America estimates that 20% to 35% of individuals with HCV are enrolled in Medicaid, which would make at least 600,000 beneficiaries candidates for the drug.

    MH Takeaways

    Medicaid plans warn that because a disproportionate share of individuals with hepatitis C are on Medicaid, the high cost of the drug will have a big impact on state Medicaid budgets.

    Medicaid plan leaders are raising concerns about the issue with state officials and Congress as they begin to set their 2015 rates. “The projected volume of patients in the Medicaid program that could benefit from this innovation, combined with the price of Sovaldi, will have a substantial impact on state Medicaid budgets,” Myers wrote in an April 28 letter to the National Association of Medicaid Directors. “The uptake of this medication will make it challenging to establish actuarially sound rates in 2015.”

    Medicaid plans in some states are considering a variety of responses to Sovaldi's cost, including eliminating coverage for the drug, having Medicaid agencies pay for it above the standard rates paid to plans, or building the drug into the rates paid by state agencies, Myers said. Medicaid agencies in California, Florida, Louisiana and Michigan already limit access to Sovaldi based on case-by-case determinations.

    David Axene, a fellow of the Society of Actuaries, also expects commercial insurers to consider additional co-pays and limiting the drug only to individuals who truly need it. “I see people asking hard questions,” he said.

    Thirty-seven states and the District of Columbia contract with private Medicaid plans, which are not eligible for the 23.1% discount that state Medicaid programs get for branded drugs under the Patient Protection and Affordable Care Act.

    Molina Healthcare offers Medicaid plans in 11 states, including California, Florida and Texas, none of which currently reimburse the company for Sovaldi. Molina has created guidelines that limit coverage for the drug to the neediest cases, which in most cases means the patient has developed cirrhosis, the final stage of chronic liver disease.

    Dr. J. Mario Molina, the company's president and CEO, said he hopes to talk with state officials about other costly drugs that may be in the pipeline. “These new drugs could be a budget buster for state Medicaid programs,” he said.

    But some experts downplay Sovaldi's impact on insurers. David Williams, president of the Health Business Group consultancy, said the cost problem should become “less acute” in the future as rival products for treating HCV reach the market, price competition increases, and the backlog of patients with longstanding HCV begins to clear.

    It could also take years for all patients who are candidates for Sovaldi to receive the drug because many don't know they have HCV, noted Alan Weil, executive director of the National Academy for State Health Policy. “So there is time to build this into future rates,” he said.

    Follow Paul Demko on Twitter: @MHPDemko

    Follow Virgil Dickson on Twitter: @MHVDickson

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    congress prescription drugs
    PBMs, Big Pharma face off in House hearing
    Biden COVID copy_i_i.jpg
    Biden administration asks employers to help more workers who lose Medicaid
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing